FDA Pauses Obesity Drug Study; Diabetic Eye Therapy OK'd; 'Misleading' Super Bowl Ad

(MedPage Today) -- The FDA ordered a clinical hold on a phase I study of the investigational obesity drug AMG 513, said developer Amgen.
Children's Hospital Los Angeles has paused initiation of puberty blockers for transgender patients under age...